On June 19th, Gelonhui reported that Tasly Pharmaceutical Group (600535.SH) stated on its investor interaction platform that the main active pharmaceutical ingredients of the company's main products, Danshen and Sanqi, are all purchased through its subsidiaries Shaanxi Shangluo and Yunnan Sanqi. The quality of raw materials is tracked and controlled to ensure large-scale and continuous supply.
天士力(600535.SH)：主要原药材丹参和三七可以保证大规模的持续供应
Tasly Pharmaceutical Group (600535.SH): The main raw materials Danshen and Sanqi can ensure large-scale and sustained supply.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.